Physician profile
Nervik Roy
NPI 1639669567
$4,554.34
in general payments reported to CMS, 2019-2025
26 companies · $1,745 in 2025
The $1,745 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.19 · 2023: $929 · 2024: $1,783 · 2025: $1,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,430 · Travel and Lodging: $26.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,429.55 |
| Travel and Lodging | $26.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $569.75 | 2023-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $444.52 | 2023-2025 | |
| Vifor Pharma, INC. | $442.49 | 2023-2025 | Veltassa, Korsuva |
| Calliditas Therapeutics US INC. | $399.43 | 2023-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $380.39 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $365.17 | 2023-2025 | Farxiga, Lokelma |
| Amgen INC. | $347.25 | 2024-2025 | Krystexxa, Tavneos |
| Fresenius USA Marketing, INC. | $340.35 | 2023-2025 | Velphoro, Velphoro |
| Ardelyx, INC. | $211.83 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.87 | 2023-2025 | Jardiance |
| Akebia Therapeutics INC | $130.79 | 2024-2025 | Vafseo |
| Glaxosmithkline, LLC. | $111.70 | 2023-2025 | Benlysta, Jesduvroq |
| Novartis Pharmaceuticals Corporation | $106.74 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $98.70 | 2023-2024 | Ultomiris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $72.81 | 2023-2025 | Jynarque |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $59.55 | 2024 | Rayaldee |
| Apellis Pharmaceuticals, INC. | $48.08 | 2025 | Empaveli |
| Aurinia Pharma U.S., INC. | $43.39 | 2024-2025 | Lupkynis |
| Daiichi Sankyo INC. | $43.29 | 2024 | Injectafer |
| Pfizer INC. | $38.51 | 2019 | |
| Mallinckrodt Hospital Products INC. | $28.73 | 2025 | Terlivaz |
| Mallinckrodt Enterprises LLC | $25.17 | 2019 | |
| Horizon Therapeutics Plc | $23.43 | 2023 | Krystexxa |
| Shire North American Group INC | $22.09 | 2019 | |
| Novo Nordisk INC | $21.89 | 2025 | Ozempic |
| E.R. Squibb & Sons, L.L.C. | $12.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nervik Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.